다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
한국임상약학회지 = Korean journal of clinical pharmacy, v.31 no.4, 2021년, pp.278 - 284
이한솔 (동덕여자대학교 약학대학) , 김종윤 (동덕여자대학교 약학대학) , 유기연 (동덕여자대학교 약학대학)
AI-Helper
Background: Osteoporosis is a disease that affects the quality of life and imposes a high socioeconomic burden. Studies have reported that statins, a HMG CoA reductase inhibitor, have a positive or negative effect on osteoporosis. The purpose of this study was to analyze the correlation between stat...
Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338(11):736-46.
Xu Y, Wu Q. Decreasing trend of bone mineral density in US multiethnic population: analysis of continuous NHANES 2005-2014. Osteoporos Int 2018;29(11):2437-46.
Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006;194(2 Suppl):S3-11.
Lorentzon M. Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med 2019;285(4):381-94.
Zethraeus N, Borgstrom F, Strom O, Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int 2007;18(1):9-23.
Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet 2019;393(10169):364-76.
Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis 2014;6(5):185-202.
Miller PD. Unrecognized and unappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am 2012;41(3):613-28.
Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodiumglucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev 2017;33(6):e2903.
Carlson BC, Robinson WA, Wanderman NR, et al. The American Orthopaedic Association's Own the Bone ® database: a national quality improvement project for the treatment of bone health in fragility fracture patients. Osteoporos Int 2018;29(9):2101-9.
Lin SM, Wang JH, Liang CC, Huang HK. Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. J Clin Endocrinol Metab 2018;103(9):3439-48.
Horodinschi RN, Stanescu AMA, Bratu OG, Pantea Stoian A, Radavoi DG, Diaconu CC. Treatment with statins in elderly patients. Medicina (Kaunas) 2019;55(11):721.
Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006;58(1):3-18.
Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286(5446):1946-9.
Lin TK, Chou P, Lin CH, Hung YJ, Jong GP. Long-term effect of statins on the risk of new-onset osteoporosis: a nationwide population-based cohort study. PLoS One 2018;13(5):e0196713.
Leutner M, Matzhold C, Bellach L, et al. Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Ann Rheum Dis 2019;78(12):1706-11.
Strilchuk L, Tocci G, Fogacci F, Cicero AFG. An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opin Pharmacother 2020;21(5):531-9.
Pena JM, Aspberg S, MacFadyen J, Glynn RJ, Solomon DH, Ridker PM. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern Med 2015;175(2):171-7.
Yilmaz A, Arikan O, Dokmetas S. Effects of statins on bone mineral density. Saudi Med J 2006;27(9):1433-5.
Committee of Clinical Practice Guideline of the Korean Society of Lipid and Atherosclerosis (KSoLA). Korean Guidelines for the Management of Dyslipidemia, 4th ed. Available from https://www.lipid.or.kr/bbs/index.html?codecare&category&gubun&page1&number957&modeview&keyfield&key. Accessed September 07, 2021.
An T, Hao J, Sun S, et al. Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos Int 2017;28(1):47-57.
Kim HJ, Koo HS, Kim YS, et al. The association of testosterone, sex hormone-binding globulin, and insulin-like growth factor-1 with bone parameters in Korean men aged 50 years or older. Journal of Bone and Mineral Metabolism 2017;35(6):659-65.
Ferrari S, Bianchi ML, Eisman JA, et al. Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 2012;23(12):2735-48.
Johnston CB, Dagar M. Osteoporosis in older adults. Med Clin North Am 2020;104(5):873-84.
Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trend Pharmacol Sci 1998;19(1):26-37.
Hatzigeorgiou C, Jackson JL. Hydroxymethylglutaryl-coenzyme a reductase inhibitors and osteoporosis: a meta-analysis. Osteoporosis International 2005;16(8):990-8.
Jadhav SB, Narayana Murthy PS, Singh MM, Jain GK. Distribution of lovastatin to bone and its effect on bone turnover in rats. J Pharm Pharmacol 2006;58(11):1451-58.
Horiuchi N, Maeda T. Statins and bone metabolism. Oral Dis 2006;12(2):85-101.
Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondly analysis of a randomized controlled trial. Lancet 2001;357(9255):509-12.
Kazi DS, Penko JM, Bibbins-Domingo K. Statins for primary prevention of cardiovascular disease: review of evidence and recommendations for clinical practice. Med Clin North Am 2017;101(4):689-99.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.